Drugs / Meropenem-Vaborbactam
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02687906 | Jul 2016 → Dec 2026 expected | bacterial infectious disease | Melinta Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06672978 | Jun 2025 → Jan 2027 expected | acute pyelonephritis | Melinta Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07004049 Comparator | Apr 2025 → Dec 2028 expected | bacterial pneumonia, infectious disease with sepsis | National University of Singapore | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meropenem-Vaborbactam | “Vabomere (meropenem-vaborbactam) for IV injection” NCT02687906 ↗ |
| Known as | Vabomere | “Vabomere (meropenem-vaborbactam) for IV injection” NCT02687906 ↗ |
| Route | Intravenous | “Vabomere (meropenem-vaborbactam) for IV injection” NCT02687906 ↗ |